



15 October 2015

ASX ANNOUNCEMENT

APPENDIX 4C – QUARTER ENDED 30 SEPTEMBER 2015

Brisbane, Australia – **ImpediMed Limited** (ASX: IPD) (“The Company”) today released its Appendix 4C – Quarterly cash flow report for the period ended 30 September 2015.

Total revenue for the quarter was \$1.5 million, including lymphoedema sales of \$0.6 million. Operating cash outflow for the quarter was \$4.8 million. Cash receipts from customers for the quarter were \$1.5 million and cash on hand as of 30 September 2015 was \$30.4 million.

Highlights;

- Lymphoedema management being included in NCCN Guidelines® for Breast Cancer for the first time
- Signed up the 5th and 6th of the six cancer centres in the US Commercial L-Dex® Pilot program

“I’m very pleased with the start of the fiscal year. Having lymphoedema included in the NCCN Guidelines for Breast Cancer for the first time was a major achievement and our preparations for the full commercial launch of L-Dex in the US marketplace later this year are progressing well,” stated Managing Director and CEO, Richard Carreon.

– ENDS –

Richard Carreon
Managing Director & CEO

For further information contact:
Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

ImpediMed Limited

ABN

65 089 705 144

Quarter ended ("current quarter")

30 September 2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter	Year to date (three months)
	\$A'000	\$A'000
1.1 Receipts from customers	1,536	1,536
1.2 Payments for		
(a) staff costs	(3,634)	(3,634)
(b) advertising and marketing	(218)	(218)
(c) research and development	(523)	(523)
(d) leased assets	(6)	(6)
(e) other working capital	(2,016)	(2,016)
1.3 Dividends received	0	0
1.4 Interest and other items of a similar nature received	17	17
1.5 Interest and other costs of finance paid	0	0
1.6 Income taxes paid	0	0
1.7 Other (provide details if material)	0	0
Net operating cash flows	(4,844)	(4,844)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (three months) \$A'000
1.8 Net operating cash flows (carried forward)	(4,844)	(4,844)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	o	o
(b) equity investments	o	o
(c) intellectual property	o	o
(d) physical non-current assets	(2)	(2)
(e) other non-current assets	o	o
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	o	o
(b) equity investments	o	o
(c) intellectual property	o	o
(d) physical non-current assets	o	o
(e) other non-current assets	o	o
1.11 Loans to other entities	o	o
1.12 Loans repaid by other entities	o	o
1.13 Other (provide details if material)	o	o
Net investing cash flows	(2)	(2)
1.14 Total operating and investing cash flows	(4,846)	(4,846)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	45	45
1.16 Release of restricted cash	o	o
1.17 Proceeds from borrowings	o	o
1.18 Repayment of borrowings	o	o
1.19 Dividends paid	o	o
1.20 Other (provide details if material)	o	o
Net financing cash flows	45	45
Net increase (decrease) in cash held	(4,801)	(4,801)
1.21 Cash at beginning of quarter/year to date	32,582	32,582
1.22 Exchange rate adjustments to item 1.20	2,593	2,593
1.23 Cash at end of quarter	30,374	30,374

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	118
1.25	Aggregate amount of loans to the parties included in item 1.11	0

1.26 Explanation necessary for an understanding of the transactions

Item 1.24: Payments to directors consist of Directors' salaries and superannuation and Directors' fees for the quarter and year-to-date. These figures include only Non-Executive Directors and exclude Directors' salaries and Directors' fees that were accrued and unpaid as at the end of the quarter. At 30 September 2015 there were \$18,750 fees accrued and unpaid.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	---	---
3.2	Credit standby arrangements	---	---

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	30,374	32,582
4.2	Deposits at call	0	0
4.3	Bank overdraft	0	0
4.4	Other (provide details)	0	0
Total: cash at end of quarter (item 1.23)		30,374	32,582

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	N/A	N/A
5.2	Place of incorporation or registration	N/A	N/A
5.3	Consideration for acquisition or disposal	N/A	N/A
5.4	Total net assets	N/A	N/A
5.5	Nature of business	N/A	N/A

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: 

Date: 15 October 2015

Print name: Morten Vigeland
Chief Financial Officer

+ See chapter 19 for defined terms.

For personal use only

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.

For personal use only